Both Corus and Tata executives talk about their desire for a friendly takeover and their common line on governance practices and business ethics.

ECONOMIST: Why the Tata-Corus deal makes sense for both parties

Genentech issued its long-awaited response to the takeover bid from drug giant Roche , which already owns 56% of the biotech bellwether, and the answer is exactly what most Wall Street analysts expected: If Roche wants a friendly takeover, it better raise its offer.

FORBES: Genentech To Roche: You're Cheap